The connective tissue diseases and the overall influence of gender

International Journal of Fertility and Menopausal Studies

Volumn 41, Issue 2, 1996, Pages 156-165

  Lahita, Robert G ^a  

^a ST LUKE S ROOSEVELT HOSPITAL CENTER   (United States)

Author keywords

(systemic) lupus erythematosus; autoimmune diseases; collagen disease(s); gender; hormones; rheumatoid arthritis; Sjogren's syndrome

Indexed keywords

ANDROGEN; CYPROTERONE; DANAZOL; NANDROLONE DECANOATE; PRASTERONE;

AUTOIMMUNITY; CONFERENCE PAPER; CONNECTIVE TISSUE DISEASE; ETIOLOGY; FEMALE; GENDER; HUMAN; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SJOEGREN SYNDROME; SYSTEMIC LUPUS ERYTHEMATOSUS;

ANIMALS; ARTHRITIS, RHEUMATOID; COLLAGEN DISEASES; CONNECTIVE TISSUE DISEASES; FEMALE; GONADAL STEROID HORMONES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; PREGNANCY; RISK FACTORS; SEX FACTORS; SJOGREN'S SYNDROME;

EID: 0030007880     PISSN: 10693130     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (121)

1. Ansar-Ahmed S, Talal N: Sex steroids, sex steroid receptors and autoimmune diseases, in Sheridan PJ, Blum K, Trachtenberg MC (eds): Steroid Receptors and Disease: Cancer, Autoimmune, Bone and Circulatory Disorders. New York and Basel, Marcel Dekker, pp 289-315, 1990.
2. Stimson WH: Sex steroids, steroid receptors and immunity, in Berczi I, Kovacs K (eds): Hormones and Immunity. The Hague, Dordrecht, MTP Press, pp 43-53, 1987.
3. Roubinian JR, Talal N, Greenspan JS: Delayed androgen treatment survival in murine lupus. J Clin Invest 63:902-911, 1979.
4. Steinberg AD, Roths JB, Murphy ED: Effects of thymectomy and androgen administration upon the autoimmune disease of MRL/Mo-lpr/lpr mice. J Immunol 125:871, 1980.
5. Cohen MG, Pollared K, Schreiber L: Relationship of age and sex to autoantibody expression in MRl +/+ and MRL Ipr mice. Clin Exp Immunol 72:50-54, 1988.
6. Raveche E, Tijo JH, Steinberg AD: Genetic studies in NZB mice. IV. The effects of sex hormones on the spontaneous production of anti-T cell antibodies. Arth Rheum 23:48, 1980.
7. Blank M, MNendlovic S, Fricke H, et al: Sex hormone involvement in the induction of experimental systemic lupus erythematosus by a pathogenic anti-DNA idiotype in naive mice. J Rheumatol 17:311-317, 1990.
8. Lahita RG: Sex and age in systemic lupus erythematosus, in Lahita RG (ed): Systemic Lupus Erythematosus. New York, John Wiley and Sons, pp 523-539, 1986.
9. Szer I, Jacobs JC: Systemic lupus erythematosus in childhood, in Lahita RG (ed): Systemic Lupus Erythematosus. New York, John Wiley and Sons, pp 383-412, 1986.
10. Inman RD: Immunologie sex differences and the femal preponderance in systemic lupus erythematosus. Arth Rheum 21:849-852, 1978.
11. Batchelor JR: Hormonal control of antibody formation, in Cinader B (ed): Regulation of Antibody Response. Springfield, IL, Charles C. Thomas, p 276, 1968.
12. Michaels RRD, Rogers KD: A sex difference in immunological responsiveness. Pediatrics 47:120- 143, 1967.
13. London WT, Drew JS: Sex differences in hepatitis B infection among patients receiving clinic dialysis treatment. Proc NatlAcad Sei USA 74:2561-2563, 1977.
14. Eidinger D, Garret TJ: Studies of the regulatory effects of sex hormones on antibody formation and stem cell differentiation. JExpMed 136:1098, 1972.
15. Butterworth MB, McClellan B, Alansmith M: Influence of sex on immunoglobulin levels. Nature 214:1225, 1967.
16. Ainbender E, Weisinger R, Hevizy M, et al: Difference in immunoglobulin class of polio antibody in the serum of men and women. J Immunol 101:1, 1968.
17. Terres G, Morrison SL, Habicht GL: A quantitative difference in the immune response between male and female mice. Proc Exp Biol Med 27:663, 1968.
18. Gable FC, Konopka EA: Sex as a factor in infectious disease. Trans NY Acad Sei 35:325-346, 1971.
19. Couchman KG, Wigley RD, Prior FAM: Autoantibodies in the Carterton population survey. J Chron Dis 23:45-53, 1970.
20. Khangure MS, Dingle PR, Staphenson J: A long-term follow-up of patients with autoimmune thyroid disease. Clin Endocrinol 6:41-48, 1977.
21. Grundbacher FJ: Human X chromosome causes quantitative genes from immunoglobulin M. Science 176:311-312, 1972.
22. Batchelor JR, Chapman BA: The influence of sex upon the antibody response to an incompatible tumor. Immunology 9:553, 1965.
23. Lahita RG, Bradlow HL, Ginzler E, et al: Low plasma androgens in women with systemic lupus erythematosus. Arth Rheum 30:241-248, 1987.
24. Stahl N, Decker J: Androgenic status of males with SLE. Arth Rheum 21:665-668, 1978.
25. Inman RD, Jovanovic L, Markenson JA: Systemic lupus erythematosus in men: genetic and endocrine features. Arch IntMed 142:1813-1815, 1982.
26. Lavalle C, Loyo E, Paniagua R, et al: Correlation study between prolactin and androgens in male patients with systemic lupus erythematosus. J Rheumatol 14:268-272, 1987.
27. Jungers P, Nahoul K, Pelissier C: Low plasma androgens in women with active or quiescent SLE. Arth Rheum 25:454-457, 1982.
28. Lahita RG, Bradlow HL, Kunkel HG, et al: Alterations of estrogen metabolism in SLE. Arth Rheum 22:1195-1198, 1979.
29. Lahita RG, Bradlow HL, Kunkel HG, et al: Increased 16 alpha hydroxylation of estradiol in systemic lupus erythematosus. J Clin Endocrinol Metab 53:174-178, 1981.
30. Lahita RG, Bradlow HL, Fishman J, et al: Estrogen metabolism in systemic lupus erythematosus: patients and family members. Arth Rheum 25:843-846, 1982.
31. Stern R, Fishman J, Brusman H, et al: Systemic lupus erythematosus associated with Klinefelter's syndrome. Arth Rheum 20:18-22, 1977.
32. Lahita RG, Bradlow HL: Klinefelter's syndrome: hormone metabolism in hypogonadal males with systemic lupus erythematosus. /Rheumatol 14(Suppl 13):154-157, 1987.
33. Bradlow HL, Fishman J: Diet and cancer [letter]. Nature 361:390, 1993.
34. Jellinck PH, Michnovicz JJ, Bradlow HL: Influence of indole-3-carbinol on the hepatic microsomal formation of catechol estrogens. Steroids 56:446-450, 1991.
35. Michnovicz JJ, Bradlow HL: Altered estrogen metabolism and excretion in humans following consumption of indole-3-carbinol. Nutr Cancer 16:59-66, 1991.
36. Michnovicz JJ, Bradlow HL: Dietary and pharmacological control of estradiol metabolism in humans. Ann NY Acad Sei 595:291-299, 1990.
37. Ortiz-Neu C, Leroy EC: The coincidence of Klinefelter syndrome and systemic lupus erythematosus. Arth Rheum 12:241-246, 1969.
38. Lahita RG, Bardlow HL, Kunkel HG, et al: Increased oxidation of testosterone in systemic lupus erythematosus. Arth Rheum 26:1517-1521, 983.
39. Fishman J, Martucci C: Biological properties of 16-alpha hydroxyestrone: implications in estrogen physiology and pathophysiology. J Clin Endocrinol Metab 51:611-615, 1980.
40. Bucala R, Fishman J, Cerami A: Formation of co-valent adducts between cortisol and 16-alpha-hydroxyestrone and protein, possible role in pathogenesis of cortisol toxicity and SLE. Proc N all Acad Sei USA 79:3320, 1982.
41. MacSween RNM: Reticulum cell carcinoma and rheumatoid arthritis in a patient with XY/XXY/ XXXY Klinefelter's syndrome and normal intelligence. Lancet 1:460, 1965.
42. Lamotte M, Labrousse C, Perrault MA, et al: Polyarthritis rheumatoid severe diabetic insulin resistant syndrome de Klinefelter. Sem Hosp Paris G 525-528, 1965.
43. Lahita RG, Chiorazzi N, Gibofsky A: Familial systemic lupus erythematosus in males. Arth Rheum 26:39, 1983.
44. Fries JF, Holman HR: Systemic Lupus Erythematosus: A Clinical Analysis. Philadelphia, W.B. Saunders, 1975.
45. Miller MH, Urowitz M, Gladman D, et al: Systemic lupus in males. Medicine 62:327-334, 1983.
46. Sthoeger ZM, Geltner D, Rider A, et al: Systemic lupus erythematosus in 49 Israeli males: a retrospective study. Clin Exp Rheum 5:223-240, 1987.
47. Kaufman LD, Gomez-Reino JJ, Heinicke MH, et al: Male lupus: retrospective analysis of the clinical and laboratory features of 52 patients, with a review of the literature. Semin Arthritis Rheum 18:189-197, 1989.
48. Alger M, Alarcon-Segovia D, Rivero Sj: Hemolytic anemia and throbocytopenic purpura: two related subsets of systemic lupus erythematosus. f Rheumatol 4:351-357, 1977.
49. Ward MM, Studenski S: Systemic lupus erythematosus in males: a multivariate analysis of gender differences in clinical manifestations. J Rheum 17:220-224, 1990.
50. Celermajer DS, Thorner PS, Baumal R, et al: Sex differences in childhood lupus nephritis. Am J Dis Child 138:586-588, 1984.
51. Masi AT, Jospipovic DJ, Jefferson WE: Low adrenal androgenic-anabolic steroid in women with rheumatoid arthritis (RA): gas-liquid Chromatographie studies of RA patient and matched normal control women indicating decreased 11-deoxy 17-ketosteroid excretion. Semin Arthritis Rheum 14:1-22, 1984.
52. Feher GK, Feher T: Plasma dehydroepiandrosterone, dehydroepiandrosterone sulphate and androsterone sulphate levels and their interaction with plasma in rheumatoid arthritis. Exp Clin Endociinol 82:197-202, 1984.
53. Wingrave SJ, Kay SR: Reduction in incidence of rheumatoid arthritis associated with oral contraceptives. Lancet 1:569-571, 1978.
54. Vandenbroucke JP, Valkenburg HA, Boersma JW, et al: Oral contraceptives and rheumatoid arthritis: further evidence for a protective effect. Lancet 2:839- 842, 1982.
55. Allebeck P, Ahlboom A, Ljungstrom K, et al: Do oral contraceptives reduce the incidence of rheumatoid arthritis? ScandJ Rheum 13:140-146, 1984.
56. Linos A, O'Fallon WM, Worthington JW, et al: Case control study of rheumatoid arthritis and prior use of oral contraceptives. Lancet 1:1299, 1983.
57. Del Junco DJ, Annegers JF, Luthra HS: Do oral contraceptives prevent rheumatoid arthritis? JAMA 254:1938-1941, 1985.
58. Vandenbroucke JP: Oral contraceptives and the risk of rheumatoid arthritis: the great transatlantic divide. Scan J Rheum 79:31-32, 1989.
59. Bijlsma JWJ, Huber-Bruning O, Thijssen JHH: Effect of estrogen treatment on clinical and laboratory manifestation of rheumatoid arthritis. Ann Rheum Dis 46:777-779, 1987.
60. Vandenbroucke JP, Witteman JCM, Valkenburg HA, et al: Noncontraceptive hormones and rheumatoid arthritis in perimenopausal and postmenopausal women. JAMA 255:1299-1303, 1986.
61. Sylvest AO: Rheumatoid arthritis and the pill. Report of two cases. Ugeski Laegei 131:1480, 1969.
62. Rudge SR, Kownko 1C, Drury PL: Menstrual cyclicity of finger joint size and grip strength of patients with rheumatoid arthritis. Ann Rheum Dis 42:425-430, 1977.
63. Pope RM, Sadyoshi Y, Rutstein J, et al: Effect of pregnancy on immune complexes and rheumatoid factors in patients with rheumatoid arthritis. Am J Med 74:973-979, 1983.
64. Hench PS: The ameliorating effect of pregnancy on chronic atrophie (infectious rheumatoid arthritis), fibrositic and intermittent hydrarthrosis. Proc Staff Meet Mayo CLin 13:161-166, 1938.
65. Ungor A, Kay A, Griffin JA, et al: Disease activity in rheumatoid arthritis during pregnancy. Br Med J 286:750-752, 1983.
66. Markoff E, Lee DW, Hollingsworth DR: Glycosylated and non-glycosylated prolactin in serum during pregnancy. J Clin Endociinol Metab 67:519-523, 1988.
67. Pekelharing JM, Hepp E, Kamerling JP, et al: Alterations in carbohydrate composition of serum IgG from patients with rheumatoid arthritis and from pregnant women. Ann Rheum Dis 47:91-95, 1988.
68. Davis M: Antigenic analysis of immune complexes formed in normal human pregnancy. Clin Exp Immunol 61:406-415, 1985.
69. Klipple G, Cecere FA: Rheumatoid arthritis and pregnancy. Rheum Dis Clin North Am 26: 213-239, 1989.
70. Berczi I: Gonadotropins and sex hormones, in Berczi I (ed): Pituitary Function and Immunity. Boca Raton, FL, CRC Press, pp 185-211, 1986.
71. Berczi I, Nagy E: Prolactin and other lactogenic hormones, in Berczi I (ed): Pituitary Function and Immunity. Boca Raton, CRC Press, pp 161-184, 1986.
72. Spector TD, Roman E, Silmon AJ: The pill, parity, and rheumatoid arthritis. Arth Rheum 33:782-789, 1990.
73. Von Shoultz B, Stigbrand T: Pregnancy zone protein: chemistry, biology and clinical studies, in Grvazinskas JG, Teisner B, Seppala H (eds): Pregnancy Proteins: Biology, Chemistry and Clinical Applications. London, Academic Press, 1982.
74. Cannon JG, Dinarello CA: Increased plasma interleukin activity in women after ovulation. Science 227:1247-1249, 1983.
75. Apppelmans M: Kerato-conjunctivite sèche de GougerotSjogren: ses rapports avec le Syndrome de Mictrulicz et la kerato-conjunctivite filameneus. Pathogenic et son traitement. Arch Ophthalmol 8:577-588, 1948.
76. Von Bruckner R: Über einen Erfolgreich mit perandren behandelten Fall von Sjögrenschem Symptomen Komplex. Ophthalmologica 110:37, 1945.
77. Radnot, Nemeth B: Wirkung der testosterone Preparate auf die Tränen Druse. Ophthalmologica 129:376-380, 1955.
78. Katayama H, Ohsawa K, Yaoita H: Improvement of progressive systemic sclerosis (PSS) with estriol treatment. Acta Derm Venereol (Stockh) 64:168-171, 1984.
79. Herbai G: Treatment of progressive systemic sclerosis with a synthetic weak estrogen: cyclofenil (Sexovid-R). Report of a case. Acta Med Scand 196(6):537-540, 1974.
80. Rau R, Pandurovic L, Boni A: Gestragenbehandlung der Sklerodermie: Bericht über Kränke. Ost Med Wschr 97:1283-1288, 1972.
81. Coplerud CP: Scleroderma. Clin Obstet Gynecol 26:587591, 1983.
82. Chapel TA, Burns RE: Oral contraceptives and exacerbations of SLE. Am J Obstet Gynecol 110:366, 1971.
83. Jungers P, Dougados M, Pelissier C, et al: Influence of oral contraceptive therapy on activity of systemic lupus erythematosus. Arth Rheum 25:618-623, 1982.
84. McKenna CH, Weiman KG, Schulman LE: Oral contraceptives, rheumatic disease and autoantibodies. Arth Rheum 12:313-314, 1969.
85. Schleicher EM: LE cells after oral contraceptives. Lancet 1:821-822, 1968.
86. Spiera H, Plotz CM: Rheumatic symptoms and oral contraceptives. Lancet 1:571-572, 1969.
87. Garovich M, Agudelo C, Pisko E: Oral contraceptives and systemic lupus erythematosus. Arth Rheum 23:13961398, 1980.
88. Ravers RL, Hughes GRV: Oral contraceptive therapy and systemic lupus erythematosus. J Rheumatol 5:448-451, 1978.
89. Poller L: Oral contraceptives, blood clotting and thrombosis. BrMed Bull 34:151-56, 1978.
90. Vessey MP: Oral contraceptives and cardiovascular disease: some questions and answers. Br Med ] 284:615-616, 1982
91. Nausieda PA, Koller WC, Weiner WJ: Chorea induced by oral contraceptives. Neurology 29:1605- 1609, 1979.
92. Fernando SJM: An attack of chorea complicating oral contraceptive therapy. Practitioner 197:210- 212, 1977.
93. Pulsinelli WA, Hamil HW: Chorea complicating oral contraceptive therapy. Case report and review of the literature. Am JMed 65:557-559, 1978.
94. Kleiger RE, Boxer M, Fryhau RE, et al: Pulmonary hypertension in patients using oral contraceptives, a report of 6 cases. Chest 69:143-147, 1976.
95. Asherson RA, Derksen RHWM, Bouma BN: Chorea in systemic lupus erythematosus and lupus-like diseases. Association with antiphospholipid antibodies. Arth Rheum 29:595 [Abstract], 1986.
96. Asherson RA, Harris EN, Gharavi AE, et al: Complications of oral contraceptives and antiphospholipid antibodies: reply to a letter by Bruneau et al. Arth Rheum 31:575-576, 1988.
97. Asherson RA, Harris EN, Gharavi AE, et al: Systemic lupus erythematosus, antiphospholipid antibodies, chorea and oral contraceptives. Arth Rheum 29: 1535-1536, 1986.
98. Bucala R, Fishman J, Cerami A: The reaction of 16-a hydroxyestrone with erythrocytes in vitro and in vivo. Eur JBiochem 140:593-598, 1984.
99. Bucala R, Lahita RG, Fishman J, et al: Anti-estrogen antibodies in users of oral contraceptives and in patients with systemic lupus erythematosus. Clin Exp Immunol 67:167-175 [Abstract], 1987.
100. Beaumont V, Lemort N, Beaumont JL: Oral contraception, circulatory immune complexes, anti ethinylestradiol antibodies and thrombosis. Am J Repiod Immunol 2:8, 1982.
101. Verheul HAM, Stimson WH, Den Hollander FC, et al: The effects of nandrolone, testosterone and their decanoate esters on murine lupus. Clin Exp Immunol 44:11-17, 1981.
102. Roubinian JR, Talal N, Greenspan JS: Danazol's failure to suppress autoimmunity in NZB/NZW Fl mice. Arth Rheum 22:1399-1402, 1979.
103. Agnello V, Pariser K, Gell J: Preliminary observation on Danazol therapy of systemic lupus: effects on DNA antibodies, thrombocytopenia and complement. J Rheumatol 10:682-687, 1983.
104. Morley KD, Parke A, Hughes GRV: SLE: two patients treated with Danazol. Br Med J 283:431, 1982.
105. Gelfand JA, Sherins RJ, Ailing DW, et al: Treatment of hereditary angioedema with danazol: reversal of clinical and biochemical abnormalities. N Engl J Med 295:1444, 1976.
106. Hauptmann G, Mayer S, Long JM: Treatment of acquired Cl-inhibitor deficiency with danazol. Ann Int Med 85:588-578, 1977.
107. Masse R, Youinou P, Doryal JC, et al: Revesal of lupus erythematosus with danazol Lancet 2:651, 1980.
108. Donaldson VH, Hess EV: Effect of danazol on lupus erythematosus like disease in hereditary angioneurotic edema. Lancet 2:1143, 1980.
109. Fretwell M, Altman LO: Exacerbation of a lupus erythematosus-like syndrome during treatment of non-Cl esterase inhibitor dependent angioedema with danazol. J Allergy Clin Immunol 69:306-310, 1982.
110. Pariser K, Gell J, Gelfond J: Pilot studies in the use of danazol in treatment of patients with systemic lupus erythematosus. Proceedings of the 15th International Congress of Rheumatology, 484 [Abstract], 1981.
111. Ahn YS, Harrington WJ, Simon SR, et al: Danazol for the treatment of idiopathic thrombocytopenic purpura. N Engl J Med 308:1396, 1983.
112. Newman F: Pharmacology and potential use of cyproterone acetate. Horm Metab Res 9:1-13, 1977.
113. Kuttenen F, Rigaud C, Wright F, et al: Treatment of hirsutism by oral cyproterone acetate and percutaneous estradiol. J Clin Endocrinol Metab 51:1107- 1111, 1980.
114. Lunell NO, Zader G, Carlstrom K: The effect of cyproterone acetate on pituitary ovarian function and clinical symptoms in hirsute women. Acta Endocrinol (Copenh) 100:91-97, 1982.
115. Jungers P, Kuttenen F, Liote F, et al: Hormonal modulation in systemic lupus erythematosus. Arth Rheum 28:12431250, 1985.
116. Mowszowicz I, Bieber DE, Chung KW: Synandrogenic and antiandrogenic effect of progestins-comparisons with non-progestational antiandrogens. Endocrinology 95:1589-1598, 1974.
117. Feher KG, Bencze G, Ujfalussy J, et al: Serum steroid hormone levels in systemic lupus erythematosus (SLE). Acta Med Hung 44:321-327, 19878.
118. Daynes RA, Dudley DJ, Araneo BA: Regulation of murine lymphokine production in vivo II. Dehydroepiandrosterone is a natural enhancer of interleukin 2 synthesis by helper T cells. Em J Immunol 20:793-802, 1990.
119. Suzuki T, Suzuki N, Engleman EG, et al: Low serum levels of dehydroepiandrosterone may cause deficient IL-2 production by lymphocytes in patients with systemic lupus erythematosus (SLE). Clin Exp Immunol 99:251255, 1995.
120. Morales AJ, Nolan JJ, Nelson JC, et al: Effects of replacement dose of dehydroepiandrosterone in men and women of advancing age. J Clin Endocrinol Metab 78:1360-137, 1994.
121. Casson PR, Andersen RH, Herod HG, et al: Oral dehydroepiandrosterone in physiologic doses modulates immune function in postmenopausal women. Am J Obstet Gynecol 169:1536, 1993.